Monoclonal Antibody Therapeutics
•150 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (150)
| Company | Market Cap | Price |
|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-1500 is a monoclonal antibody therapeutic, a core biologic drug candidate developed by Tonix.
|
$150.25M |
$17.13
+7.74%
|
|
IPHA
Innate Pharma S.A.
Lacutamab and monalizumab are monoclonal antibodies, aligning with Monoclonal Antibody Therapeutics.
|
$146.12M |
$1.75
-0.85%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$131.50M |
$2.35
-0.42%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$129.63M |
$2.15
+9.69%
|
|
CNTX
Context Therapeutics Inc.
CTX's products are therapeutic antibodies (monoclonal antibody therapeutics) used for cancer.
|
$129.17M |
$1.44
-5.59%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$126.95M |
$2.11
+1.93%
|
|
STRO
Sutro Biopharma, Inc.
ADC therapies are a form of monoclonal antibody–based therapeutics, aligning with Sutro's antibody-drug conjugate products.
|
$117.16M |
$13.72
+4.97%
|
|
FBIO
Fortress Biotech, Inc.
UNLOXCYT (cosibelimab-ipdl) asset involves a monoclonal antibody, fitting Monoclonal Antibody Therapeutics.
|
$110.69M |
$3.73
+7.04%
|
|
PYXS
Pyxis Oncology, Inc.
ADC therapy leveraging a monoclonal antibody to deliver a cytotoxic payload.
|
$109.15M |
$1.76
-4.35%
|
|
MGNX
MacroGenics, Inc.
MacroGenics has approved monoclonal antibody assets (MARGENZA, ZYNYZ, TZIELD) and focuses on monoclonal antibody therapeutics.
|
$108.71M |
$1.72
|
|
AGEN
Agenus Inc.
Botensilimab (BOT) and balstilimab (BAL) are monoclonal antibody therapeutics targeting CTLA-4 and PD-1 pathways.
|
$106.43M |
$3.35
-8.83%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
CRB-601 is a monoclonal antibody therapeutic, placing Corbus in the monoclonal antibody therapeutics space.
|
$101.96M |
$8.36
+2.33%
|
|
MREO
Mereo BioPharma Group plc
Setrusumab is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$101.82M |
$0.64
-4.64%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 involves oral delivery of monoclonal antibodies, aligning with monoclonal antibody therapeutics.
|
$99.90M |
$1.41
+1.08%
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$92.33M |
$1.96
+2.08%
|
|
PLRX
Pliant Therapeutics, Inc.
PLN-101325 is a monoclonal antibody agonist targeting integrin α7β1, representing a direct antibody therapeutic program.
|
$79.19M |
$1.29
+1.17%
|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$78.35M |
$2.58
+1.78%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
EQ
Equillium, Inc.
Itolizumab is a monoclonal antibody therapeutic, mapping to Monoclonal Antibody Therapeutics.
|
$76.16M |
$1.20
-6.64%
|
|
CMPX
Compass Therapeutics, Inc.
Company develops Monoclonal Antibody Therapeutics for oncology applications.
|
$71.97M |
$5.69
-1.90%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$67.75M |
$1.02
+2.00%
|
|
ANL
Adlai Nortye Ltd.
ANL’s antibody-based therapeutics position the company within Monoclonal Antibody Therapeutics as a related category.
|
$66.35M |
$1.66
-1.19%
|
|
LVTX
LAVA Therapeutics N.V.
The company focuses on antibody-based therapeutics (monoclonal antibody–type products) for cancer via its Gammabody platform.
|
$45.77M |
$1.65
-5.17%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$43.91M |
$3.61
+0.28%
|
|
IBIO
iBio, Inc.
IBIO is developing monoclonal antibody therapeutics (e.g., IBIO-101, IBIO-600, Activin E antibodies).
|
$43.24M |
$2.21
+0.23%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Actinium employs monoclonal antibodies (e.g., lintuzumab) as targeting components in its antibody-based radiotherapies.
|
$41.49M |
$1.34
+2.29%
|
|
FGEN
FibroGen, Inc.
FG-3246 utilizes a monoclonal antibody payload (YS5), aligning with Monoclonal Antibody Therapeutics.
|
$39.28M |
$9.53
+5.60%
|
|
XLO
Xilio Therapeutics, Inc.
Vilastobart is an anti-CTLA-4 monoclonal antibody, aligning with Monoclonal Antibody Therapeutics.
|
$37.95M |
$0.73
+0.33%
|
|
SKYE
Skye Bioscience, Inc.
Nimacimab is a monoclonal antibody therapeutic targeting CB1, making Monoclonal Antibody Therapeutics the direct product category.
|
$37.19M |
$1.20
-0.42%
|
|
NXTC
NextCure, Inc.
ADCs are based on monoclonal antibodies delivering cytotoxic payloads, fitting the Monoclonal Antibody Therapeutics category.
|
$34.55M |
$13.08
+1.63%
|
|
RADX
Radiopharm Theranostics Limited
Antibody-based therapeutics (PSA-mAb and B7-H3 mAb) used in radiopharmaceutical contexts.
|
$33.93M |
$5.18
+0.68%
|
|
DYAI
Dyadic International, Inc.
C1 platform has been used to produce monoclonal antibodies targeting RSV and malaria in legacy biopharma programs.
|
$31.49M |
$0.85
-4.49%
|
|
RLYB
Rallybio Corporation
Lead programs are monoclonal antibody therapeutics (RLYB116 and RLYB332).
|
$27.45M |
$0.65
-4.05%
|
|
IKNA
Ikena Oncology, Inc.
IMG-007 is a monoclonal antibody therapeutic, placing the company in the Monoclonal Antibody Therapeutics category.
|
$26.26M |
$6.53
|
|
OTLK
Outlook Therapeutics, Inc.
Bevacizumab is a monoclonal antibody; ONS-5010 is a monoclonal antibody therapeutic formulated for ophthalmic use.
|
$26.21M |
$0.60
+2.54%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$24.87M |
$1.53
+0.66%
|
|
AKTX
Akari Therapeutics, Plc
ADC uses monoclonal antibodies, aligning with monoclonal antibody therapeutics.
|
$20.35M |
$0.28
-31.68%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Monoclonal antibody therapeutics tag reflects LIMN's lead anti-CD47 antibody program as a targeted biologic for cancer.
|
$20.01M |
$0.75
-3.68%
|
|
BCAB
BioAtla, Inc.
Evalstotug is a CAB-CTLA-4 antibody, a monoclonal antibody therapeutic.
|
$18.92M |
$0.33
+3.25%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$18.63M |
$8.62
-1.54%
|
|
KAPA
Kairos Pharma, Ltd.
ENV-105 is a monoclonal antibody therapeutic (CD105 antagonist) in development.
|
$18.10M |
$0.87
-1.96%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$14.84M |
$0.95
-8.64%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$13.53M |
$2.94
-0.68%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Solnerstotug is a monoclonal antibody therapeutic targeting VISTA, aligning with Monoclonal Antibody Therapeutics.
|
$13.17M |
$11.11
-4.31%
|
|
BOLT
Bolt Biotherapeutics, Inc.
The company develops monoclonal antibody therapeutics (e.g., BDC-3042) as part of its ISAC platform.
|
$12.21M |
$6.40
-8.31%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$10.27M |
$1.45
+2.11%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaPro's high-affinity B7-H3 antibodies represent monoclonal antibody therapeutics.
|
$8.08M |
$4.30
-4.12%
|
|
IMRN
Immuron Limited
Antibody-based therapeutics (monoclonal antibody category) reflects Immuron's antibody-focused therapy approach.
|
$6.04M |
$1.08
+0.93%
|
|
HCWB
HCW Biologics Inc.
Second-generation pembrolizumab-based constructs and antibody-based ICIs fit Monoclonal Antibody Therapeutics.
|
$2.97M |
$1.36
+19.30%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$359547 |
$0.14
|
Showing page 2 of 2 (150 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
